General Information of Drug (ID: DM06GDC)

Drug Name
T2c-001 Drug Info
Synonyms
T2c-001-AMI; T2c-001-CHD; T2c-001-DCM; T2c-001-SW; Autologous bone marrow-derived endothelial progenitor cell therapy, Goethe University/t2cure; Autologous endothelial progenitor cells (myocardial infarction), Goethe University/t2cure; Endothelial progenitor cell therapy (ischemia), Goethe University/t2cure
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM06GDC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting T-cells (T-cells)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ATG-Fresenius S DM4VJ5Q Transplant rejection NE84 Phase 3 [3]
DiabeCell DMK6FYR Insulin-dependent diabetes 5A10 Phase 2 [2]
TVI-Kidney-1 DMGYSZ0 Renal cell carcinoma 2C90 Phase 2 [4]
Baltaleucel-T DM3WCL4 Diffuse large B-cell lymphoma 2A81 Phase 2 [5]
BPX-501 DMIMA4V Acute lymphoblastic leukaemia 2A85 Phase 1/2 [5]
AX-024 DMRQ32K Multiple sclerosis 8A40 Phase 1 [6]
RTL-1000 DM1B4CQ Multiple sclerosis 8A40 Phase 1 [7]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cells (T-cells) TTXQYT6 NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT01693042) Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure. U.S. National Institutes of Health.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Clinical pipeline report, company report or official report of Neovii Biotech.
4 Clinical pipeline report, company report or official report of TVAX Biomedical.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14.